血浆 EBV DNA 作为 EBV 相关胃癌的预后因素:一项多中心、前瞻性研究(EBV PRESAGE 研究)。
Plasma EBV DNA as a prognostic factor in EBV associated gastric cancer: a multicenter, prospective study (EBV PRESAGE study).
发表日期:2023
作者:
Andrea Alberti, Gertraud Stocker, Florian Lordick, Ulrich T Hacker, Benjamin Kobitzsch, Ivonne Haffner, Gian Luca Baiocchi, Manuel Zamparini, Guido A M Tiberio, Carla Baronchelli, Arnaldo Caruso, Paolo Bossi, Alfredo Berruti
来源:
Experimental Hematology & Oncology
摘要:
癌症基因组图谱研究网络将 Epstein-Barr 病毒 (EBV) 阳性胃癌确定为一种独特的分子亚型。患病率为 8-9%,组织学检查显示明显的淋巴细胞浸润、IFN-γ 水平升高以及由此导致的 PD-L1 过度表达。血浆 EBV DNA 载量作为该癌症亚型患者预后因素的作用仍有待确定。目前涉及德国和意大利癌症中心的多中心前瞻性观察研究“EBV PRESAGE”旨在评估血浆 EBV 的预后作用EBV 相关胃癌 (GC) 中的 DNA。目的是研究不同连续时间点的血浆 EBV DNA 载量与患者预后之间的关系。每一位新诊断出胃癌(包括胃食管交界腺癌)的患者都将使用原位杂交 (ISH) 在组织活检中筛查 Epstein-Barr 编码的小区域 (EBER)。如果 EBER ISH 呈阳性,将进行血浆 EBV DNA 血液分析。血浆EBV定量分析将集中进行,血浆样本中EBV DNA的提取、检测和定量将使用实时PCR进行。我们假设血浆EBV DNA代表了监测EBV相关GC和的非侵入性工具。作为预后标记可能很有价值。版权所有 © 2023 Alberti、Stocker、Lordick、Hacker、Kobitzsch、Haffner、Baiocchi、Zamparini、Tiberio、Baronchelli、Caruso、Bossi 和 Berruti。
The Cancer Genome Atlas Research Network identified Epstein-Barr-Virus (EBV)-positive gastric cancer as a distinct molecular subtype. The prevalence is 8-9% and the histological examination shows pronounced lymphocytic infiltration, elevated levels of IFN-γ and consequently overexpression of PD-L1. The role of plasma EBV DNA load as a prognostic factor in patients with this cancer subtype is still to be defined.The present multicenter prospective observational study "EBV PRESAGE", involving German and Italian cancer centers, aims to evaluate the prognostic role of plasma EBV DNA in EBV-related gastric cancer (GC). The objective is to study the association between plasma EBV DNA load at different consecutive time points and the patient's prognosis. Every patient with a new diagnosis of gastric cancer (including gastroesophageal junction adenocarcinoma) will be screened for Epstein-Barr encoded small Region (EBER) on tissue biopsies using in situ hybridization (ISH). If EBER ISH is positive, blood analysis for plasma EBV DNA will be conducted. The plasma EBV quantitative analysis will be centralized, and extraction, detection, and quantification of EBV DNA in plasma samples will be performed using real-time PCR.We hypothesized that plasma EBV DNA represents a non-invasive tool for monitoring EBV-related GC and might be valuable as a prognostic marker.Copyright © 2023 Alberti, Stocker, Lordick, Hacker, Kobitzsch, Haffner, Baiocchi, Zamparini, Tiberio, Baronchelli, Caruso, Bossi and Berruti.